Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 14/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423753 | 0.93 | GRIA2 (0.51) | GRIA2CYP2C9CYP2D6CNR1CNR2 | |
| SCHEMBL1424279 | 0.89 | GRIA2 (0.71) | GRIA2CYP2C9CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL1423823 | 0.89 | GRIA2 (0.74) | GRIA2CYP2C9CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL1424465 | 0.85 | GRIA2 (0.78) | GRIA2CYP2C9CYP2D6CNR1CNR2 | |
| SCHEMBL1424041 | 0.81 | GRIA2 (0.62) | GRIA2CYP2C9CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL1424200 | 0.80 | GRIA2 (0.54) | GRIA2CYP2C9CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL8165348 | 0.78 | GRIA2 (0.60) | GRIA2CYP2C9CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL1423711 | 0.78 | GRIA2 (0.66) | GRIA2CYP2C9CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL1423600 | 0.77 | GRIA2 (0.55) | GRIA2CYP2C9CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL8163366 | 0.75 | GRIA2 (0.71) | GRIA2CYP2C9CYP2D6CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086643-B1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2011-03-23 | — | — | EP | claimed |
| EP-2086643-B1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20100137276-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137276-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GRIN1, GRM2, GRIN3A | GRIA2 23/4885CYP2C9 2591/4885CYP2D6 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.